CTRI/2019/08/020536已完成未知
An Open label, Multi-centre, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Multiple-dose, Steady-state, Cross-over, Bioequivalence study of Quetiapine Fumarate tablets 300 mg of Prinston Pharmaceutical Inc. comparing with that of SEROQUEL® (Quetiapine Fumarate) tablets 300 mg of AstraZeneca Pharmaceuticals LP, USA when administered twice daily in adult schizophrenia patients already receiving Quetiapine in a stable regimen.
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1Male or female aged 18-65 years (both inclusive) with BMI 18 to 35 kg/m2
- •2Patients with clinically diagnosis of Schizophrenia (DSM-IV-TR) and who are in a stable regimen of Quetiapine 300 mg twice daily atleast one month prior to screening
- •3Not having any significant diseases or abnormal findings except schizophrenia.
- •4Acceptable Haematological parameters, Hepatic and Renal function at screening
- •5Patient should have adequate ability to provide decision for informed consent along with legally acceptable representative.
- •6Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal women for at least 12 consecutive months, must agree to use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile sexual partner for at least 2 weeks prior to the study and up to 30 days after the last dose of the study drug
- •7In case of male patients: Either partner or patient must use an effective method of contraception for avoiding pregnancy for at least 2 weeks prior to the study drug administration, during the study and up to 30 days after the last dose
排除标准
- •i.History of Hypersensitivity to Quetiapine or any of the excipients of study drug.
- •ii.Patient with dementia related psychosis.
- •iii.Patient with a history of Neuroleptic malignant Syndrome (NMS).
- •iv.Any psychiatric illness (Other than Schizophrenia) neurological disorders, including neurologic malignant syndrome, major depressive disorder, organic mental disorder, severe tardive dyskinesia, Parkinsonâ??s disease, history or presence of epilepsy or risk for seizures, history of multiple syncopal episodes or stroke.
- •v.Patient who had undergone exacerbation of Schizophrenia and ECT (Electro convulsive therapy) within two months from the screening.
- •vi.History of suicidal tendencies or or immediate risk of harm to self or other (e.g. suicidal attempts) within the past 2 months prior to screening as judged by the investigator.
- •vii.Patient with history or presence of seizures or other conditions that potentially lower the seizure threshold, cognitive and motor impairment.
- •viii.Hospitalization for an exacerbation of schizophrenia with in two Months.
- •ix.Patient with significant clinical relevant endocrinal, cerebrovascular, pulmonary, haematological, immunological and cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities, cardiomyopathy, myocarditis), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). Could lead to safety risk.
- •x.History or presence of circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including: bradycardia, cardiac arrhythmias, hypokalemia or hypomagnesemia, concomitant use of other drugs that prolong the QTc interval; and presence of congenital prolongation of the QT interval (QTc > 440 ms).
- •xi.Presence of uncontrolled metabolic disorders including uncontrolled diabetes mellitus (Fasting blood glucose levels greater than 160 mg/dl and HbA1c greater than or equal 8%), Serum total cholesterol greater than or equal 300 mg/dl and fasting serum triglyceride levels greater than or equal 300 mg/dl.
- •xii.Patient with clinically significant hyperprolactinemia or with possible prolactin dependent tumor.
- •xiii.Patient with known hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose¬galactose malabsorption.
- •xiv.Patient having Systolic Blood Pressure >= 140 mm Hg or Diastolic Blood Pressure >= 90 mm Hg.
- •xv.Use of any of the following medications within 14 days prior to enrolment but not limited to:
- •Strong inhibitors of CYP3A4
- •Strong inducers of CYP3A4
- •Drugs associated with QT prolongation
- •Antihypertensive and other drugs known to cause hypotension
- •xvi.Female patient with Positive Pregnancy test.
- •xvii.Patient with known positivity for human immunodeficiency virus (HIV), HBsAg or HCV.
- •xviii.Patient had major surgery within 2 months prior to study entry, or who have not recovered from prior major surgery.
- •xix.Patient with history of venous thromboembolism or conditions that predispose the risk of embolism.
- •xx.Medical or surgical condition that might interfere with the absorption, metabolism or excretion of Quetiapine.
- •xxi.Patient with
研究者
相似试验
进行中（未招募）
不适用
A study of Capecitabine 200 mg/ ml with Xeloda 500 mg (Capecitabine) at a dose of 2000 mg in adult human cancer patients under fed conditions.CTRI/2020/10/028417Shilpa Medicare Limited
进行中（未招募）
Unknown
euprolide acetate in the treatment of Prostate Cancer.CTRI/2023/09/057619Pharmathen S.A.
已完成
不适用
Imatinib Mesylate Oral Solution 400mg/5ml with Gleevec® (Imatinib mesylate) Tablets 400mg in adult human subjects with Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumors under fed condition.CTRI/2020/03/024404Shilpa Medicare Limited35
已完成
不适用
Open label multicenter randomized parallel single-period single dose bio equivalence study of Leuprolide acetate 30 mg in adult male subjects with advanced prostaticcancer undergoing initial therapy.CTRI/2020/10/028442Pharmathen SA32
已完成
不适用
To evaluate bioavailability of oral Capecitabine in adult human cancer patients under fed conditionsCTRI/2021/06/034321ShilpaMedicareLimited35